EGFR and cancer: Previous data indicated that uPAR induced the resistance to anti-cancer agents via the EGFR/p-AKT signaling pathway, as observed in gefitinib-resistant human lung adenocarcinoma cells [30] and vemurafenib-resistant melanoma cells [31].